Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 32, 2013, Pages 12881-12886

  Alabi, Christopher A ^a,b   Love, Kevin T ^a   Sahay, Gaurav ^a   Yin, Hao ^a   Luly, Kathryn M ^c   Langer, Robert ^a,b   Anderson, Daniel G ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c University of Rochester   (United States)

Author keywords

Drug carrier; Gene silencing; RNAi; Thiol yne

Indexed keywords

LIPID; NANOCARRIER; NANOPARTICLE; SMALL INTERFERING RNA;

ARTICLE; CELL MEMBRANE; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR STABILITY; PARTICLE SIZE; PHYSICAL CHEMISTRY; PKA; PRIORITY JOURNAL; RNA TRANSPORT; STRUCTURE ACTIVITY RELATION;

DRUG CARRIER; GENE SILENCING; RNAI; THIOL-YNE;

ANIMALS; FACTOR VII; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE TRANSFER TECHNIQUES; HELA CELLS; HEMOLYSIS; HUMANS; LIPIDS; LUCIFERASES; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; NANOPARTICLES; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84881408604     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1306529110     Document Type: Article

References (41)

1. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov 8(2):129-138.
2. Kumari A, Kumar V, Yadav SK (2011) Nanocarriers: A tool to overcome biological barriers in siRNA delivery. Expert Opin Biol Ther 11(10):1327-1339.
3. Wang J, Lu Z, Wientjes MG, Au JL-S (2010) Delivery of siRNA therapeutics: Barriers and carriers. Am Assoc Pharm Sci J 12(4):492-503.
4. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol Pharm 6(3):659-668.
5. Akinc A, et al. (2009) Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther 17(5):872-879.
6. Santel A, et al. (2006) A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 13(16):1222-1234.
7. Rozema DB, et al. (2007) Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA 104(32):12982-12987.
8. Tang Y, et al. (2012) Efficient in vitro siRNA delivery and intramuscular gene silencing using PEG-modified PAMAM dendrimers. Mol Pharm 9(6):1812-1821.
9. Alabi C, Vegas A, Anderson D (2012) Attacking the genome: Emerging siRNA nanocarriers from concept to clinic. Curr Opin Pharmacol 12(4):427-433.
10. Merkel OM, et al. (2009) Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: Effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. J Control Release 138(2):148-159.
11. Buyens K, et al. (2008) A fast and sensitive method for measuring the integrity of siRNA-carrier complexes in full human serum. J Control Release 126(1):67-76.
12. Mescalchin A, et al. (2007) Cellular uptake and intracellular release are major obstacles to the therapeutic application of siRNA: Novel options by phosphorothioatestimulated delivery. Expert Opin Biol Ther 7(10):1531-1538.
13. Dominska M, Dykxhoorn DM (2010) Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 123(Pt 8):1183-1189.
14. Alabi CA, et al. (2012) FRET-labeled siRNA probes for tracking assembly and disassembly of siRNA nanocomplexes. ACS Nano 6(7):6133-6141.
15. Kwon YJ (2012) Before and after endosomal escape: Roles of stimuli-converting siRNA/polymer interactions in determining gene silencing efficiency. Acc Chem Res 45(7):1077-1088.
16. Zhang J, Fan H, Levorse DA, Crocker LS (2011) Interaction of cholesterol-conjugated ionizable amino lipids with biomembranes: Lipid polymorphism, structure-activity relationship, and implications for siRNA delivery. Langmuir 27(15):9473-9483.
17. Zhang J, Fan H, Levorse DA, Crocker LS (2011) Ionization behavior of amino lipids for siRNA delivery: Determination of ionization constants, SAR, and the impact of lipid pKa on cationic lipid-biomembrane interactions. Langmuir 27(5):1907-1914.
18. Philipp A, Zhao X, Tarcha P, Wagner E, Zintchenko A (2009) Hydrophobically modified oligoethylenimines as highly efficient transfection agents for siRNA delivery. Bioconjug Chem 20(11):2055-2061.
19. Jayaraman M, et al. (2012) Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 51(34):8529-8533.
20. Heyes J, Palmer L, Bremner K, MacLachlan I (2005) Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release 107(2):276-287.
21. Gratton SEA, et al. (2008) The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 105(33):11613-11618.
22. Akinc A, et al. (2008) A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26(5):561-569.
23. Love KT, et al. (2010) Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107(5):1864-1869.
24. Whitehead KA, et al. (2012) In vitro-in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery. Am Chem Soc Nano 6(8):6922-6929.
25. Akinc A, et al. (2010) Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18(7):1357-1364.
26. Leuschner F, et al. (2011) Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 29(11):1005-1010.
27. Novobrantseva TI, et al. (2012) Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells. Mol Ther Nucleic Acids 1:e4.
28. Semple SC, et al. (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28(2):172-176.
29. Fitzgerald K et al. (2012) Phase I safety, pharmacokinetic and pharmacodynamic results for ALN-PCS: A novel RNAi therapeutic for the treatment of hypercholesterolemia (Alnylam Pharmaceuticals, Cambridge, MA). Available at http://www.alnylam.com/capella/wp-content/uploads/2012/04/ALN-PCS-PhaseI-ATVB- April20-2012.pdf. Accessed September 8, 2012.
30. Alnylam Pharmaceuticals (2011) Trial to evaluate safety and tolerability of ALN-PCS02 in subjects with elevated LDL-cholesterol (LDL-C). (Registry of Federally and Privately Supported Clinical Trials, US National Institutes of Health, Bethesda). Available at http://clinicaltrials.gov/ct2/show/NCT01437059. Accessed July 15, 2013.
31. Alnylam Pharmaceuticals (2012) Trial to evaluate safety, tolerability, and pharmacokinetics of ALN-TTR02 in healthy volunteer subjects. (Registry of Federally and Privately Supported Clinical Trials, US National Institutes of Health, Bethesda). Available at http://clinicaltrials.gov/show/NCT01559077. Accessed July 15, 2013.
32. Hobo W, et al. (2013) Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother 62(2):285-297.
33. Ruponen M, et al. (2001) Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes. J Biol Chem 276(36):33875-33880.
34. Ruponen M, Honkakoski P, Tammi M, Urtti A (2004) Cell-surface glycosaminoglycans inhibit cation-mediated gene transfer. J Gene Med 6(4):405-414.
35. Nguyen J, Szoka FC (2012) Nucleic acid delivery: The missing pieces of the puzzle? Acc Chem Res 45(7):1153-1162.
36. Varkouhi AK, Scholte M, Storm G, Haisma HJ (2011) Endosomal escape pathways for delivery of biologicals. J Control Release 151(3):220-228.
37. Evans WH, Hardison WG (1985) Phospholipid, cholesterol, polypeptide and glycoprotein composition of hepatic endosome subfractions. Biochem J 232(1):33-36.
38. Demaurex N (2002) pH Homeostasis of cellular organelles. News Physiol Sci 17:1-5.
39. Bailey AL, Cullis PR (1994) Modulation of membrane fusion by asymmetric transbilayer distributions of amino lipids. Biochemistry 33(42):12573-12580.
40. Varga CM, Hong K, Lauffenburger DA (2001) Quantitative analysis of synthetic gene delivery vector design properties. Mol Ther 4(5):438-446.
41. Bartlett DW, Davis ME (2006) Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 34(1):322-333.